An Investigation of Cardiovascular Risks in a Group of Children and Adolescents Who Use Atypical Antipsychotics

References

• Aktepe, E. (2011). Çocuk ve ergenlerde psikotrop ilaçlarin endokrin ve metabolik yan etkileri. TAF Preventive Medicine Bulletin, 10(6), 741–750.
   Google Scholar
• Altıntaş, K., & Böke, Ö. (2014). Yeni kuşak antipsikotiklerin metabolik yan etkileri. Psikiyatride Güncel Yaklaşımlar, 1(4), 251–252.
   Google Scholar
• American Diabetes Association. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596–601.
   PubMed Web of Science ®Google Scholar
• Aşık, E., Albayrak, S., & Erdoğan, N. (2016). Hemşirelerin antipsikotik ilaç kullanan hastalarda metabolik sendrom riskine yönelik uygulamalari. Clinical and Experimental Health Science, 6, 161–165.
   Google Scholar
• Ayık, B., & Erdoğan, A. (2015). Çocuk ve ergenlerde görülen psikotik bozukluklarin tedavisinde kullanilan atipik antipsikotikler. Turkiye Klinikleri Journal of Child Psychiatry-Special Topics, 1(3), 39–53.
   Google Scholar
• Baker, J. L., Olsen, L. W., & Sørensen, T. I. (2007). Childhood body-mass index and the risk of coronary heart disease in adulthood. New England Journal of Medicine, 357(23), 2329–2337.
   PubMed Web of Science ®Google Scholar
• Biederman, J., Mick, E., Hammerness, P., Harpold, T., Aleardi, M., Dougherty, M., & Wozniak, J. (2005). Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biological Psychiatry, 58(7), 589–594.
   PubMed Web of Science ®Google Scholar
• Bressington, D., Mui, J., Hulbert, S., Cheung, E., Bradford, S., & Gray, R. (2014). Enhanced physical health screening for people with severe mental illness in Hong Kong: Results from a one-year prospective case series study. BMC Psychiatry, 14(1), 2–10.
   PubMed Web of Science ®Google Scholar
• Bressington, D., Mui, J., Tse, M. L., Gray, R., Cheung, E. F., & Chien, W. T. (2016). Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: A cross-sectional study. BMC Psychiatry, 16(1), 2–14.
   PubMed Web of Science ®Google Scholar
• Çelik, G. G., Tahiroğlu, A., & Avcı, A. (2011). Çocuk ve ergenlerde atipik antipsikotik ilaçlarin metabolik ve endokrin yan etkileri. Psikiyatride Güncel Yaklaşımlar, 3(2), 232–250.
   Google Scholar
• Çetin, M. (2014). A serious risk: Excessive and inappropriate antipsychotic prescribing. Bulletin of Clinical Psychopharmacology, 24(1), 1–4.
   Google Scholar
• Çetin, M., & Turgay, A. (2002). Modern psikofarmakolojinin ellinci yilinda klorpromazinden günümüze: Antipsikotik tedavinin dünü, bugünü. Bulletin of Clinical Psychopharmacology, 12, 211–226.
   Google Scholar
• Cook, S., Weitzman, M., Auinger, P., Nguyen, M., & Dietz, W. H. (2003). Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988–1994. Archives of Pediatrics & Adolescent Medicine, 157(8), 821–827.
   PubMedGoogle Scholar
• Correll, C. U. (2007). Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. The Journal of Clinical Psychiatry, 69, 26–36.
   Web of Science ®Google Scholar
• Correll, C. U., & Carlson, H. E. (2006). Endocrin and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 771–791.
   PubMed Web of Science ®Google Scholar
• Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302(16), 1765–1773.
   PubMed Web of Science ®Google Scholar
• De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H. J. (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry, 24(6), 412–424.
   PubMed Web of Science ®Google Scholar
• Ebrinç, S., Çetin, M., & Öner, Ö. (2014). Özel gruplarda bipolar bozukluk tedavisinde atipik antipsikotikler. Bulletin of Clinical Psychopharmacology, 14, 236–250.
   Google Scholar
• Ergün, G., Isik, I., & Dikec, G. (2017). Roles of psychiatry nurses within a therapeutic environment of psychiatry clinics in turkey. Archives of Psychiatric Nursing, 31(3), 248–255.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2016). Retrieved from: http://www.fda.gov (Accessed December 21, 2016).
   Google Scholar
• Güleç-Öyekçin, D. (2009). Bir grup şizofreni ve şizoaffektif bozukluk hastasında metabolik sendrom sıklığı. Anadolu Psikiyatri Dergisi, 10, 26–33.
   Google Scholar
• Güveli, H., İlnem, M. C., Yener, F., Karamustafalıoğlu, F., İpekçioğlu, D., & Abanoz, Z. (2011). Antipsikotik kullanan şizofren hastalarinda metabolik sendrom sikliği ve ilişkili etmenleri. New/Yeni Symposium Journal, 49(2), 67–76.
   Google Scholar
• Hardy, S., Hinks, P., & Gray, R. (2013). Screening for cardiovascular risk in patients with severe mental illness in primary care: A comparison with patients with diabetes. Journal of Mental Health, 22(1), 42–50.
   PubMed Web of Science ®Google Scholar
• Ivanov, I., & Chaney, A. (2008). Treating pediatric patients with antipsychotic drugs: balancing benefits and safety. Mount Sınaı Journal of Medicine, 75, 276–286.
   PubMed Web of Science ®Google Scholar
• Jerrell, J. M., & McInytre, R. S. (2008). Adverse events in children and adolescents treated with antipsychotic medications. Human Psychopharmacolgy, 23, 283–290.
   PubMed Web of Science ®Google Scholar
• Kutlu, R., Çivi, S., & Karaoğlu, O. (2011). Can waist circumference clinically be useful as a predictor of obesity/underweight in children? Gulhane Medical Journal, 53(3), 170–176.
   Google Scholar
• McIntyre, R. S., & Jerrell, J. M. (2008). Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents archives of pediatrics & adolescent. Archives of Pediatrics & Adolescent Medicine, 162(10), 929–935.
   PubMed Web of Science ®Google Scholar
• Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., & Newcomer, J. W. et al. (2010). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics & Adolescent Medicine, 164(4), 344–351.
   PubMed Web of Science ®Google Scholar
• Nasrallah, H. A. (2008). Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles. Molecular Psychiatry, 13, 27–35.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. (2016). Psychosis and schizophrenia in children and young people: Recognition and management. Retrieved from: https://www.nice.org.uk/guidance/CG155/chapter/Recommendations#possiblepsychosis (Accessed December 26, 2017).
   Google Scholar
• Pearson, G. S. (2012). Managing the metabolic side effects of atypical antipsychotics. Journal of Child and Adolescent Psychiatric Nursing, 25, 54–55.
   PubMedGoogle Scholar
• Perez-Pınar, M., Mathur, R., Foguet, Q., Ayis, S., Robson, J., & Ayerbe, L. (2016). Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders. European Psychiatry, 35, 8–15.
   PubMed Web of Science ®Google Scholar
• Quintana, H., Wilson, M., Purnell, W., Layman, A., & Mercante, D. (2007). An open-label study of olanzapine in children and adolescents with schizophrenia. Journal of Psychiatric Practice, 13(2), 86–96.
   PubMedGoogle Scholar
• Ramdour, S., Duxbury, J. A., Becket, G., & Wilson, S. (2015). A cross-sectional observational study of healthcare professional views of factors affecting teenage adherence with antipsychotic medication. Journal of Psychiatric and Mental Health Nursing, 22, 491–501.
   PubMed Web of Science ®Google Scholar
• Schneider, C., Taylor, D., Zalsman, G., Frangou, S., & Kyriakopoulos, M. (2014). Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. Journal of Psychopharmacology, 28(7), 615–623.
   PubMed Web of Science ®Google Scholar
• Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29(1), 133–145.
   PubMed Web of Science ®Google Scholar
• Uğur, M. (2008). Atipik antipisikotik ilaçlar ve psikozlu hastalarda ortaya ç>kan metabolik sendrom. In Ayhan Songar II (ed.), Davranış fizyolojisi sempozyumu (pp. 51–59). İstanbul: Nobel Tıp Kitapevleri.
   Google Scholar
• Ushey, K., Foster, K., & Park, T. (2006). The metabolic syndrome and schizophrenia: The latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing, 13, 730–734.
   PubMed Web of Science ®Google Scholar
• Varol-Taş, F., Güvenir, T., & Miral, S. (2007). Bir Çocuk ve ergen psikiyatri kliniğinde yatarak tedavi gören hastalarda ilaç kullanımı. Çocuk ve Gençlik Ruh Sağlığı Dergisi, 14(3), 139–150.
   Google Scholar
• Vitiello, B. (2012). Principles in using psychotropic medication in children and adolescents. In J. M. Rey (Ed.), IACAPAP e-Textbook of child and adolescent mental health. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions, 1–21.
   Google Scholar
• Xiao, S., Baker, C., & Oyewumi, L. K. (2012). Psychosocial processes influencing weight management among persons newly prescribed atypical antipsychotic medications. Journal of Psychiatric and Mental Health Nursing, 19, 241–247.
   PubMed Web of Science ®Google Scholar
• Yılmaz, S., & Buzlu, S. (2006). Liverpool Üniversitesi antipsikotiklerin yan etki değerlendirme ölçeği'nin Türkçe formunun güvenilirliği. Klinik Psikofarmakoloji Bülteni, 16(3), 147–154.
   Google Scholar
• Yüksel, N., & Sayın, A. (2006). Antipsikotiklere bağli metabolik yan etkiler. Klinik Psikiyatri, 9(Supp. 1), 5–16.
   Google Scholar